Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Leqvio inclisiran Primary hypercholesterolemia Do not reimburse Complete
Waymade-Trientine trientine hydrochloride Wilson's Disease Reimburse with clinical criteria and/or conditions Complete
Bijuva estradiol and progesterone Vasomotor symptoms associated with menopause Reimburse with clinical criteria and/or conditions Complete
Ultomiris ravulizumab Paroxysmal nocturnal hemoglobinuria Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Gastroesophageal junction or esophageal adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Libtayo cemiplimab Basal cell carcinoma Reimburse with clinical criteria and/or conditions Complete
Adtralza tralokinumab atopic dermatitis Do not reimburse Complete
Myinfla colchicine Atherothrombotic events in coronary artery disease Do not reimburse Complete
Ngenla somatrogon Growth hormone deficiency Reimburse with clinical criteria and/or conditions Complete
Lorbrena lorlatinib ALK-positive locally advanced or metastatic non-small cell lung Reimburse with clinical criteria and/or conditions Complete